Comparative Pharmacology
Head-to-head clinical analysis: PENTAM versus PROTOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENTAM versus PROTOSTAT.
PENTAM vs PROTOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pentamidine is an antiprotozoal agent that interferes with nucleotide and nucleic acid synthesis, possibly by binding to DNA and inhibiting RNA and protein synthesis. It also affects membrane integrity and inhibits oxidative phosphorylation.
Proto-oncogene tyrosine-protein kinase Src inhibitor; inhibits cell proliferation and induces apoptosis in cancer cells overexpressing Src.
4 mg/kg intravenously once daily for 21 days (Pneumocystis jirovecii pneumonia); or 300 mg deep intramuscularly every 3 weeks for prophylaxis.
250 mg orally three times daily after meals for 7-10 days; alternatively, 500 mg twice daily for 7 days.
None Documented
None Documented
Clinical Note
moderatePentamidine + Gatifloxacin
"Pentamidine may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderatePentamidine + Rosoxacin
"Pentamidine may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderatePentamidine + Trovafloxacin
"Pentamidine may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderatePentamidine + Nalidixic acid
"Pentamidine may increase the hypoglycemic activities of Nalidixic acid."
Terminal elimination half-life: 6-24 hours (prolonged in renal impairment; up to 48 hours in anuria).
8 hours (range 6-10 h); in renal impairment, half-life prolonged up to 20 hours; dose adjustment required for CrCl < 30 mL/min.
Renal: approximately 60-70% unchanged; biliary/fecal: minimal, <10%.
Renal: 70% as unchanged drug; biliary/fecal: 15% as metabolites; 15% other.
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent